NCT06987539 2026-03-16
THYME
Amgen
Phase 2 Recruiting
Clinical Trials
7 trialsNCT04524273 2026-03-10
MINT
Amgen
Phase 3 Active not recruiting
NCT00983619 2020-05-13
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
MedImmune LLC
Phase 1/2 Completed
NCT01861340 2018-09-10
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT01453205 2018-03-12
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
MedImmune LLC
Phase 2 Completed
NCT01957579 2017-06-12
A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
AstraZeneca
Phase 1 Completed
NCT01466153 2017-05-31
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 2 Completed